Reduced efficacy has also been observed in triple nucleoside combinations and these should also be avoided [77]. In the case of dual infection, a baseline genotypic resistance test for HIV-1, and if possible for HIV-2, should be performed. Antiviral drugs known to be active against both viruses should be given and both HIV-1 and HIV-2 RNA levels should be measured periodically Midostaurin nmr [78]. Treatment failure despite low baseline HIV-2 viral load is not uncommon [47,51] and viral load response is significantly lower than that seen in HIV-1 [34]. Prophylaxis and treatment should be given as for HIV-1. Please refer to the BHIVA guidelines for Pregnancy, 1.11 section 14 [79]. Group chair: Jane Anderson,

Homerton University Hospital NHS Foundation selleck kinase inhibitor Trust, London, UK. Group deputy chair: Yvonne Gilleece, Brighton and Sussex University Hospital NHS Trust, Brighton, UK. Members: Judith Breuer, University College, London, UK; David Hawkins, Chelsea and Westminster Hospital, London, UK; Erasmus Smit, West Midlands Public Health

Laboratory, Birmingham, UK; Li Xu McCrae, West Midlands Public Health Laboratory, Birmingham, UK; David Chadwick, The James Cook University Hospital, Middlesbrough, UK; Deenan Pillay, University College London, London, UK; Nicola Smith, Chelsea and Westminster Hospital, London, UK. “
“Combination antiretroviral therapy (cART) has become the main driver of total costs of caring for persons living with HIV (PLHIV).

The present study estimated the short/medium-term cost trends in response to the recent evolution of national guidelines and regional therapeutic protocols for cART in Italy. We developed a deterministic mathematical model that was calibrated using epidemic data for Lazio, a region located in central Italy with about six million inhabitants. In the NADPH-cytochrome-c2 reductase Base Case Scenario, the estimated number of PLHIV in the Lazio region increased over the period 2012–2016 from 14 414 to 17 179. Over the same period, the average projected annual cost for treating the HIV-infected population was €147.0 million. An earlier cART initiation resulted in a rise of 2.3% in the average estimated annual cost, whereas an increase from 27% to 50% in the proportion of naïve subjects starting cART with a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen resulted in a reduction of 0.3%. Simplification strategies based on NNRTIs co-formulated in a single tablet regimen and protease inhibitor/ritonavir-boosted monotherapy produced an overall reduction in average annual costs of 1.5%. A further average saving of 3.3% resulted from the introduction of generic antiretroviral drugs. In the medium term, cost saving interventions could finance the increase in costs resulting from the inertial growth in the number of patients requiring treatment and from the earlier treatment initiation recommended in recent guidelines.